DNp73 Exerts Function in Metastasis Initiation by Disconnecting the Inhibitory Role of EPLIN on IGF1R-AKT/STAT3 Signaling

Cancer Cell

Volumn 24, Issue 4, 2013, Pages 512-527

  Steder, Marc ^a   Alla, Vijay ^a   Meier, Claudia ^a   Spitschak, Alf ^a   Pahnke, Jens ^b   Fürst, Katharina ^a   Kowtharapu, BhavaniS ^a   Engelmann, David ^a   Petigk, Janine ^a   Egberts, Friederike ^c   Schäd Trcka, SusanneG ^d   Gross, Gerd ^d   Nettelbeck, DirkM ^e   Niemetz, Annett ^a   Pützer, BrigitteM ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN BINDING PROTEIN; DNP73 PROTEIN; EPLIN PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PROTEIN; PROTEIN KINASE B; PROTEIN P73; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; UVOMORULIN;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SIZE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DEREGULATION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MICROMETASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84885344813     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.023     Document Type: Article

References (45)

1. Abe K., Takeichi M. EPLIN mediates linkage of the cadherin catenin complex to F-actin and stabilizes the circumferential actin belt. Proc. Natl. Acad. Sci. USA 2008, 105:13-19.
2. All-Ericsson C., Girnita L., Seregard S., Bartolazzi A., Jager M.J., Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest. Ophthalmol. Vis. Sci. 2002, 43:1-8.
3. Alla V., Engelmann D., Niemetz A., Pahnke J., Schmidt A., Kunz M., Emmrich S., Steder M., Koczan D., Pützer B.M. E2F1 in melanoma progression and metastasis. J.Natl. Cancer Inst. 2010, 102:127-133.
4. Buhlmann S., Pützer B.M. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim. Biophys. Acta 2008, 1785:207-216.
5. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
6. Chapuis N., Tamburini J., Cornillet-Lefebvre P., Gillot L., Bardet V., Willems L., Park S., Green A.S., Ifrah N., Dreyfus F., et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2010, 95:415-423.
7. Chen S., Maul R.S., Kim H.R., Chang D.D. Characterization of the human EPLIN (Epithelial Protein Lost in Neoplasm) gene reveals distinct promoters for the two EPLIN isoforms. Gene 2000, 248:69-76.
8. Davies M.A., Stemke-Hale K., Lin E., Tellez C., Deng W., Gopal Y.N., Woodman S.E., Calderone T.C., Ju Z., Lazar A.J., et al. Integrated molecular and clinical analysis of AKT activation in metastatic melanoma. Clin. Cancer Res. 2009, 15:7538-7546.
9. Domínguez G., García J.M., Peña C., Silva J., García V., Martínez L., Maximiano C., Gómez M.E., Rivera J.A., García-Andrade C., Bonilla F. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative invivo network involving p73 isoforms, p53, and E2F-1. J.Clin. Oncol. 2006, 24:805-815.
10. Emmrich S., Wang W., John K., Li W., Pützer B.M. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth invivo. Mol. Cancer 2009, 8:61.
11. Fernández Y., Verhaegen M., Miller T.P., Rush J.L., Steiner P., Opipari A.W., Lowe S.W., Soengas M.S. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res. 2005, 65:6294-6304.
12. Gallagher W.M., Bergin O.E., Rafferty M., Kelly Z.D., Nolan I.-M., Fox E.J.P., Culhane A.C., McArdle L., Fraga M.F., Hughes L., et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 2005, 26:1856-1867.
13. Govindarajan B., Sligh J.E., Vincent B.J., Li M., Canter J.A., Nickoloff B.J., Rodenburg R.J., Smeitink J.A., Oberley L., Zhang Y., et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J.Clin. Invest. 2007, 117:719-729.
14. Grille S.J., Bellacosa A., Upson J., Klein-Szanto A.J., van Roy F., Lee-Kwon W., Donowitz M., Tsichlis P.N., Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003, 63:2172-2178.
15. Hazan R.B., Qiao R., Keren R., Badano I., Suyama K. Cadherin switch in tumor progression. Ann. N Y Acad. Sci. 2004, 1014:155-163.
16. Hoek K.S., Eichhoff O.M., Schlegel N.C., Döbbeling U., Kobert N., Schaerer L., Hemmi S., Dummer R. Invivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008, 68:650-656.
17. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin. Cancer Res. 2007, 13:1362-1366.
18. Huber A.H., Stewart D.B., Laurents D.V., Nelson W.J., Weis W.I. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J.Biol. Chem. 2001, 276:12301-12309.
19. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
20. Jean D., Gershenwald J.E., Huang S., Luca M., Hudson M.J., Tainsky M.A., Bar-Eli M. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J.Biol. Chem. 1998, 273:16501-16508.
21. Jiang W.G., Martin T.A., Lewis-Russell J.M., Douglas-Jones A., Ye L., Mansel R.E. Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol. Cancer 2008, 7:71.
22. Lindsay J., McDade S.S., Pickard A., McCloskey K.D., McCance D.J. Role of DeltaNp63γ in epithelial to mesenchymal transition. J.Biol. Chem. 2011, 286:3915-3924.
23. Malmlöf M., Pääjärvi G., Högberg J., Stenius U. Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol. Sci. 2008, 102:232-240.
24. Masuda N., Kato H., Nakajima T., Sano T., Kashiwabara K., Oyama T., Kuwano H. Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers. Cancer Sci. 2003, 94:612-617.
25. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
26. Petrenko O., Zaika A., Moll U.M. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation invivo. Mol. Cell. Biol. 2003, 23:5540-5555.
27. Qian X., Karpova T., Sheppard A.M., McNally J., Lowy D.R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J. 2004, 23:1739-1748.
28. Rickman D.S., Millon R., De Reynies A., Thomas E., Wasylyk C., Muller D., Abecassis J., Wasylyk B. Prediction of future metastasis and molecular characterization of head and neck squamous-cell carcinoma based on transcriptome and genome analysis by microarrays. Oncogene 2008, 27:6607-6622.
29. Rosenbluth J.M., Mays D.J., Pino M.F., Tang L.J., Pietenpol J.A. A gene signature-based approach identifies mTOR as a regulator of p73. Mol. Cell. Biol. 2008, 28:5951-5964.
30. Sanders A.J., Martin T.A., Ye L., Mason M.D., Jiang W.G. EPLIN is a negative regulator of prostate cancer growth and invasion. J.Urol. 2011, 186:295-301.
31. Slade N., Zaika A.I., Erster S., Moll U.M. DeltaNp73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ. 2004, 11:357-360.
32. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
33. Sousa J.F., Espreafico E.M. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer 2008, 8:19.
34. Stiewe T., Theseling C.C., Pützer B.M. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J.Biol. Chem. 2002, 277:14177-14185.
35. Stiewe T., Zimmermann S., Frilling A., Esche H., Pützer B.M. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res. 2002, 62:3598-3602.
36. Stiewe T., Stanelle J., Theseling C.C., Pollmeier B., Beitzinger M., Pützer B.M. Inactivation of the RB tumor suppressor gene by oncogenic isoforms of the p53 family member p73. J.Biol. Chem. 2003, 278:14230-14236.
37. Tannapfel A., John K., Mise N., Schmidt A., Buhlmann S., Ibrahim S.M., Pützer B.M. Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008, 29:211-218.
38. Tuve S., Wagner S.N., Schittek B., Pützer B.M. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int. J. Cancer 2004, 108:162-166.
39. Wang S.P., Wang W.L., Chang Y.L., Wu C.T., Chao Y.C., Kao S.H., Yuan A., Lin C.W., Yang S.C., Chan W.K., et al. p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat. Cell Biol. 2009, 11:694-704.
40. VanBrocklin M.W., Verhaegen M., Soengas M.S., Holmen S.L. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res. 2009, 69:1985-1994.
41. Wolter K.G., Verhaegen M., Fernández Y., Nikolovska-Coleska Z., Riblett M., de la Vega C.M., Wang S., Soengas M.S. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ. 2007, 14:1605-1616.
42. Xie T.X., Huang F.J., Aldape K.D., Kang S.H., Liu M., Gershenwald J.E., Xie K., Sawaya R., Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66:3188-3196.
43. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
44. Zhang S., Wang X., Osunkoya A.O., Iqbal S., Wang Y., Chen Z., Müller S., Chen Z., Josson S., Coleman I.M., et al. EPLIN downregulation promotes epithelial-mesenchymal transition in prostate cancer cells and correlates with clinical lymph node metastasis. Oncogene 2011, 30:4941-4952.
45. Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J.Biol. Chem. 2000, 275:15099-15105.